Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
Billing and coding articles A54386, A54418, A54422 and 9 more: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A54386 (Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID® Update), Billing and Coding A54418 (Billing and Coding: MolDX: FDA-Approved BRAF Tests), Billing and Coding A54422 (Billing and Coding: MolDX: FDA-Approved EGFR Tests), Billing and Coding A54445 (Billing and Coding: MolDX: MammaPrint), Billing and Coding A54480 (Billing and Coding: MolDX: Oncotype DX® Breast Cancer Assay), Billing and Coding A54484 (Billing and Coding: MolDX: Oncotype DX® Colon Cancer), Billing and Coding A54498 (Billing and Coding: MolDX: FDA-Approved KRAS Tests), Billing and Coding A55711 (Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)), Billing and Coding A56103 (Billing and Coding: MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors), Billing and Coding A57526 (Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT)), Billing and Coding A57842 (Billing and Coding: MolDX: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268)), Billing and Coding A59641 (Billing and Coding: MolDX: Proteomics Testing) carry the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A54386: Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID® Update (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 255
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 1
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C02.1 | Malignant neoplasm of border of tongue |
| C08.9 | Malignant neoplasm of major salivary gland, unspecified |
| C09.9 | Malignant neoplasm of tonsil, unspecified |
| C11.8 | Malignant neoplasm of overlapping sites of nasopharynx |
| C15.3 | Malignant neoplasm of upper third of esophagus |
| C15.4 | Malignant neoplasm of middle third of esophagus |
| C15.5 | Malignant neoplasm of lower third of esophagus |
| C15.9 | Malignant neoplasm of esophagus, unspecified |
| C16.0 | Malignant neoplasm of cardia |
| C16.2 | Malignant neoplasm of body of stomach |
| C16.8 | Malignant neoplasm of overlapping sites of stomach |
| C16.9 | Malignant neoplasm of stomach, unspecified |
| C17.9 | Malignant neoplasm of small intestine, unspecified |
| C18.0 | Malignant neoplasm of cecum |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C22.0 | Liver cell carcinoma |
| C22.1 | Intrahepatic bile duct carcinoma |
| C22.7 | Other specified carcinomas of liver |
| C22.8 | Malignant neoplasm of liver, primary, unspecified as to type |
| C22.9 | Malignant neoplasm of liver, not specified as primary or secondary |
Procedure codes: 81540.
A54418: Billing and Coding: MolDX: FDA-Approved BRAF Tests (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 56
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 1
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.0 | Malignant neoplasm of anus, unspecified |
| C21.1 | Malignant neoplasm of anal canal |
| C21.2 | Malignant neoplasm of cloacogenic zone |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| C43.0 | Malignant melanoma of lip |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.31 | Malignant melanoma of nose |
Procedure codes: 81210.
A54422: Billing and Coding: MolDX: FDA-Approved EGFR Tests (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 12
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 1
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
Procedure codes: 81235.
A54445: Billing and Coding: MolDX: MammaPrint (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 36
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 3
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
Procedure codes: 81479, 81521, 81523.
A54480: Billing and Coding: MolDX: Oncotype DX® Breast Cancer Assay (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 55
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 1
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
Procedure codes: 81519.
A54484: Billing and Coding: MolDX: Oncotype DX® Colon Cancer (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 13
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 1
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.1 | Malignant neoplasm of anal canal |
Procedure codes: 81525.
A54498: Billing and Coding: MolDX: FDA-Approved KRAS Tests (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 37
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 3
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C77.0 | Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck |
| C77.1 | Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes |
| C77.2 | Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes |
| C77.3 | Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes |
| C77.4 | Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes |
| C77.5 | Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes |
| C77.8 | Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions |
| C77.9 | Secondary and unspecified malignant neoplasm of lymph node, unspecified |
| C78.01 | Secondary malignant neoplasm of right lung |
| C78.02 | Secondary malignant neoplasm of left lung |
| C78.1 | Secondary malignant neoplasm of mediastinum |
| C78.2 | Secondary malignant neoplasm of pleura |
| C78.39 | Secondary malignant neoplasm of other respiratory organs |
| C78.4 | Secondary malignant neoplasm of small intestine |
| C78.5 | Secondary malignant neoplasm of large intestine and rectum |
| C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| C78.80 | Secondary malignant neoplasm of unspecified digestive organ |
| C78.89 | Secondary malignant neoplasm of other digestive organs |
| C79.01 | Secondary malignant neoplasm of right kidney and renal pelvis |
| C79.02 | Secondary malignant neoplasm of left kidney and renal pelvis |
| C79.11 | Secondary malignant neoplasm of bladder |
| C79.19 | Secondary malignant neoplasm of other urinary organs |
| C79.2 | Secondary malignant neoplasm of skin |
Procedure codes: 81275, 81276, 81479.
A55711: Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML) (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 2
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 2
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
Procedure codes: 81120, 81121.
A56103: Billing and Coding: MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 0
- 0 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 4
- Full article
- cms.gov record
Procedure codes: 81301, 81479, 88341, 88342.
A57526: Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (Billing and Coding, effective 2026-10-01)
- Covered ICD-10-CM codes
- 0
- 0 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 713
- Full article
- cms.gov record
Procedure codes: 0001U, 0004M, 0005U, 0006M, 0007M, 0008U, 0011M, 0012M, 0013M, 0016M, 0016U, 0017M, 0017U, 0018U, 0019U, 0020M, 0022U, 0023U, 0026U, 0027U, 0030U, 0032U, 0034U, 0036U, 0037U, 0040U, 0045U, 0046U, 0047U, 0048U, 0049U, 0050U, 0055U, 0060U, 0069U, 0070U, 0071U, 0072U, 0073U, 0074U and 673 more in the article.
A57842: Billing and Coding: MolDX: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268) (Billing and Coding, effective 2026-02-19)
- Covered ICD-10-CM codes
- 0
- 0 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 5
- Full article
- cms.gov record
Procedure codes: 81265, 81266, 81267, 81268, 81479.
A59641: Billing and Coding: MolDX: Proteomics Testing (Billing and Coding, effective 2026-10-01)
- Covered ICD-10-CM codes
- 0
- 0 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 63
- Full article
- cms.gov record
Procedure codes: 0002M, 0002U, 0003M, 0003U, 0015M, 0019M, 0021U, 0080U, 0092U, 0095U, 0105U, 0117U, 0166U, 0174U, 0206U, 0207U, 0228U, 0247U, 0249U, 0259U, 0263U, 0295U, 0308U, 0309U, 0310U, 0312U, 0322U, 0344U, 0351U, 0360U, 0365U, 0366U, 0367U, 0375U, 0384U, 0385U, 0387U, 0407U, 0412U, 0415U and 23 more in the article.
Coverage indications, limitations and medical necessity
This coverage policy provides the following information:
• defines tests required to register for a unique identifier
• defines tests required to submit a complete technical assessment (TA) for coverage determination
• defines the payment rules applied to covered tests that are not reported with specific codes from a code set recognized in 45 CFR §162.1002(a)(5), and termed "HIPAA compliant code sets" throughout the remainder of this LCD
• lists specific covered tests that have completed the registration and TA process and meet Medicare’s reasonable and necessary criteria for coverage.
Tests evaluated through the application process and/or technical assessment will be reviewed to answer the following questions:
• Is the test performed in the absence of clinical signs and symptoms of disease?
• Will the test results provide the clinician with information that will improve patient outcomes and/or change physician care and treatment of the patient?
• Will the test results confirm a diagnosis or known information?
• Is the test performed to determine risk for developing a disease or condition?
• Will risk assessment change management of the patient?
• Is there a diagnosis specific indication to perform the test?
• Is the test performed to measure the quality of a process or for Quality Control/Quality Assurance (QC/QA), i.e., a test to ensure a tissue specimen matches the patient?
Molecular Diagnostic Test (MDT) Policy Specific Definitions
MDT: Any test that involves the detection or identification of nucleic acid(s) deoxyribonucleic acid/ribonucleic acid (DNA/RNA), proteins, chromosomes, enzymes, cancer chemotherapy sensitivity and/or other metabolite(s). The test may or may not include multiple components. A MDT may consist of a single mutation analysis/identification, and/or may or may not rely upon an algorithm or other form of data evaluation/derivation.
Laboratory developed test (LDT): Any test developed by a laboratory developed without Food and Drug Administration (FDA) approval or clearance.
Applicable Tests/Assays
In addition to the MDT definition, this coverage policy applies to all tests that meet at least one of the following descriptions:
• All non-FDA approved/cleared laboratory developed tests (LDT)
• All modified FDA-approved/cleared kits/tests/assays
• All tests/assays billed with more than one code from a HIPAA compliant code set to identify the service, including combinations of method-based, serology-based, and anatomic pathology codes
• All tests that meet the first three bullets and are billed with a Not Otherwise Classified NOC code
Unique Test Identifier Requirement
Because the available language in the current HIPAA compliant code sets used to describe the pathology and laboratory categories and the tests included in those categories are not specific to the actual test results provided, all MDT services must include an identifier as additional claim documentation. Test providers must receive an identifier specific to the applicable test and submit the test assigned identifier with the claim for reimbursement. The assigned identifier will provide a crosswalk between the test’s associated detail information on file and the submitted claim detail line(s) required to adjudicate each test’s claim. The unique identifier limits the need to submit the required additional information about the test on each claim.
Technology Assessments (TA)
Molecular Diagnostic Services Program (MolDX ® ) will review all new test/assay clinical information to determine if a test meets Medicare’s reasonable and necessary requirement. Labs must submit a comprehensive dossier on each new test/assay prior to claim submission. MolDX ® will only cover and reimburse tests that demonstrate analytical and clinical validity, and clinical utility at a level that meets the Medicare reasonable and necessary requirement.
Payment Rules
MolDX ® will reimburse:
• approved tests covered for dates of service consistent with the effective date of the coverage determination.
Covered Tests
Please refer to the MolDX ® website www.palmettogba.com/MolDX for covered and excluded tests' specific coding and billing information.
Other tests/assays may be addressed by separate Noridian policy. In addition, the CPT codes listed under Group 1 are addressed in the MolDX ® program. If a test is not linked below under Related Local Coverage Documents, it may be addressed under separate Noridian policy or it has not been approved for coverage as it has either not been vetted by the MolDX ® contractor or has been found to be considered statutorily excluded.
For additional MolDX ® Program information, go to the Noridian Medicare home page at noridianmedicare.com and select MolDX ® under the Policies Tab.
MolDX ® expects laboratory providers to follow test indications published by the developer.
Summary of evidence (opening)
N/A
the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2015-10-01
- Current revision effective
- 2026-02-05
- Last reviewed by the contractor
- 2025-09-29
- MCD version
- 62
- Derived from
- L33541
Other related documents: A54552 (Response to Comments), A54553 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Noridian Healthcare Solutions, LLC hub lists every other active policy from the same contractor.
The same policy title at other contractors
Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L35160 cover?
• defines the payment rules applied to covered tests that are not reported with specific codes from a code set recognized in 45 CFR §162.1002(a)(5), and termed "HIPAA compliant code sets" throughout the remainder of this LCD The full 729-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L35160 apply to?
Noridian Healthcare Solutions, LLC applies it to Medicare claims in 13 states plus 3 territories: AK, AS, AZ, CA, GU, HI, ID, MP, MT, ND, NV, OR, SD, UT, WA, WY. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L35160?
The companion billing and coding article A54386 lists 255 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L35160?
A denial under LCD L35160 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A54386's 255 covered diagnosis codes, then file a redetermination with Noridian Healthcare Solutions, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.